0001104659-22-120752.txt : 20221121 0001104659-22-120752.hdr.sgml : 20221121 20221121160518 ACCESSION NUMBER: 0001104659-22-120752 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221118 FILED AS OF DATE: 20221121 DATE AS OF CHANGE: 20221121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Drutz David CENTRAL INDEX KEY: 0001428764 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 221405774 MAIL ADDRESS: STREET 1: 8601 SIX FORKS ROAD STREET 2: SUITE 160 CITY: RALEIGH STATE: NC ZIP: 27615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 4 1 tm2231089-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-11-18 0 0001326190 Altimmune, Inc. ALT 0001428764 Drutz David C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S GAITHERSBURG MD 20878 1 0 0 0 Common Stock, par value $0.0001 2022-11-18 4 M 0 139 2.4 A 20151 D Common Stock, par value $0.0001 333 I See Footnote Stock Options (option to buy) 2.4 2022-11-18 4 M 0 139 0 D 2022-12-31 Common Stock, par value $0.0001 139 0 D Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. This option is fully vested and exercisable as of the date hereof. /s/ Richard Eisenstadt, as Attorney-in-Fact 2022-11-21